Scholarlink

Background <p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide induce rapid weight loss, including facial adipose reduction, which may accelerate sagging due to loss of soft-tissue support. Preventive strategies remain unvalidated, and prospective trials are challenging.</p> Objective <p>To evaluate in silico whether prophylactic injectable treatments along lateral facial vectors mitigate sagging during one year of semaglutide-associated weight loss and compare efficacy across product classes.</p> Methods <p>A large-scale virtual randomized trial was conducted using the AESTHETISIM™ platform. A total of 12,000 digital twins (adults aged 30–50, BMI &gt;30 kg/m<sup>2</sup>) were randomized into six arms: control, hyaluronic acid (HA), hyperdiluted calcium hydroxylapatite (CaHA), hybrid HA+CaHA, poly-L-lactic acid (PLLA), and a bio-remodelling injectable. All received simulated semaglutide exposure. A finite-element biomechanical model incorporated compartment-specific fat loss, gravitational loading, ligament support, and time-dependent dermal adaptation. The primary endpoint was a facial sagging index (FSI) based on inferior landmark displacement; secondary endpoints included midface descent and jawline curvature. Bayesian hierarchical models provided comparative inference.</p> Results <p>All prophylactic injectable strategies reduced facial sagging relative to control (posterior probability &gt;0.99). At 12 months, CaHA achieved the greatest reduction in facial sagging index (ΔFSI −2.74 mm), followed by HA+CaHA (−2.60 mm) and the bio-remodelling injectable (−2.41 mm). Hyaluronic acid demonstrated a strong early effect with subsequent attenuation (−1.11 mm), whereas poly-L-lactic acid showed a delayed and modest benefit within the one-year horizon (−1.30 mm). Mechanistic analyses indicated that durable sagging prevention was driven primarily by increased resistance to creep and redistribution of lateral facial loads rather than transient volumization. An exploratory multi-session sensitivity analysis showed that a second prophylactic session produced modest late-phase improvement for slower-acting agents, particularly poly-L-lactic acid (additional ≈0.5 mm reduction in facial sagging index at 12 months), without altering the overall one-year superiority of CaHA-based strategies.</p> Conclusions <p>Prophylactic lateral-vector injectables reduced facial sagging in this virtual trial. Within the modelled parameter space, CaHA-based strategies predicted the greatest one-year protection. PLLA’s delayed action may be underrepresented in single-session designs. These findings provide proof-of-concept support for preventive aesthetic approaches in GLP-1 RA patients and generate testable hypotheses requiring prospective clinical validation. The comparative rankings observed should be interpreted as model-derived predictions contingent on underlying parameter assumptions rather than definitive clinical evidence.</p> Level of Evidence IV <p>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors &#xa0;<a href="http://www.springer.com/00266">www.springer.com/00266</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Computational Trial of Prophylactic Biostimulator Interventions to Mitigate Facial Sagging Associated With GLP-1 Receptor Agonist Induced Weight Loss

  • 期刊论文

  • 发表日期：

    2026年7月7日

查看全文
  • Eqram Rahman,
  • Alain Michon,
  • Parinitha Rao,
  • Golam Saklayen,
  • Munim Ahmed,
  • John H Joseph,
  • Woffles T. L. Wu,
  • William Richard Webb

摘要

Background

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide induce rapid weight loss, including facial adipose reduction, which may accelerate sagging due to loss of soft-tissue support. Preventive strategies remain unvalidated, and prospective trials are challenging.

Objective

To evaluate in silico whether prophylactic injectable treatments along lateral facial vectors mitigate sagging during one year of semaglutide-associated weight loss and compare efficacy across product classes.

Methods

A large-scale virtual randomized trial was conducted using the AESTHETISIM™ platform. A total of 12,000 digital twins (adults aged 30–50, BMI >30 kg/m2) were randomized into six arms: control, hyaluronic acid (HA), hyperdiluted calcium hydroxylapatite (CaHA), hybrid HA+CaHA, poly-L-lactic acid (PLLA), and a bio-remodelling injectable. All received simulated semaglutide exposure. A finite-element biomechanical model incorporated compartment-specific fat loss, gravitational loading, ligament support, and time-dependent dermal adaptation. The primary endpoint was a facial sagging index (FSI) based on inferior landmark displacement; secondary endpoints included midface descent and jawline curvature. Bayesian hierarchical models provided comparative inference.

Results

All prophylactic injectable strategies reduced facial sagging relative to control (posterior probability >0.99). At 12 months, CaHA achieved the greatest reduction in facial sagging index (ΔFSI −2.74 mm), followed by HA+CaHA (−2.60 mm) and the bio-remodelling injectable (−2.41 mm). Hyaluronic acid demonstrated a strong early effect with subsequent attenuation (−1.11 mm), whereas poly-L-lactic acid showed a delayed and modest benefit within the one-year horizon (−1.30 mm). Mechanistic analyses indicated that durable sagging prevention was driven primarily by increased resistance to creep and redistribution of lateral facial loads rather than transient volumization. An exploratory multi-session sensitivity analysis showed that a second prophylactic session produced modest late-phase improvement for slower-acting agents, particularly poly-L-lactic acid (additional ≈0.5 mm reduction in facial sagging index at 12 months), without altering the overall one-year superiority of CaHA-based strategies.

Conclusions

Prophylactic lateral-vector injectables reduced facial sagging in this virtual trial. Within the modelled parameter space, CaHA-based strategies predicted the greatest one-year protection. PLLA’s delayed action may be underrepresented in single-session designs. These findings provide proof-of-concept support for preventive aesthetic approaches in GLP-1 RA patients and generate testable hypotheses requiring prospective clinical validation. The comparative rankings observed should be interpreted as model-derived predictions contingent on underlying parameter assumptions rather than definitive clinical evidence.

Level of Evidence IV

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors  www.springer.com/00266.